The ongoing phase I/IIa PETRA trial (NCT04644068) has enrolled 61 patients with advanced HER2-negative breast, ovarian, prostate, or pancreatic cancer who had germline or somatic BRCA1/2, PALB2, or RAD51C/D loss-of-function mutations. Here, PALB2 is linked to familial pancreatic carcinoma.